I posted the original comment, but there are multiple reasons why math success won't translate into drug development or materials engineering success.
It is easy to create verifiable rewards environments for math and coding, and use the resulting data for RLVR post-training. For other domains you need machines or robots creating and running experiments. This is simply something that's never been attempted at scale.
Getting IPO level monies should enable the amount of capital needed to sustain such efforts, and if I were a betting man, that is going to be Anthropic's actual endgame given their nascent efforts in automating bio research.
Getting IPO level monies should enable the amount of capital needed to sustain such efforts, and if I were a betting man, that is going to be Anthropic's actual endgame given their nascent efforts in automating bio research.